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Abstract
Background: Increased numbers of Interleukin-17-producing CD4
+ T cells (Th17) have been found in association
with hepatitis B virus (HBV)-induced liver injury. However, the mechanism underlying the increase of Th17
responses in patients with HBV infection remains unclear. In this study, we investigate the possible regulatory
mechanisms of increased Th17 responses in patients with chronic hepatitis B(CHB).
Methods: Th17 response and IL-6R expression on CD4
+ T cells in peripheral blood samples were determined by
flow cytometry. Cytokines TGF-b, IL-1b, IL-6 and IL-17 in plasma and/or supernatant samples were determined by
ELISA and the IL-17 and IL-6R mRNA levels were quantified by quantitative real-time reverse polymerase chain
reaction.
Results: All these data indicated that the frequency of periphery Th17 cells is significantly correlated with the
percentage of CD4
+ T cells expressing IL-6R in CHB patients. CD4
+ T cells from patients with CHB, but not those
from healthy donors, produced higher levels of IL-17 and had more IL-6R expression upon stimulation with the
HBV core antigen (HBcAg) in vitro. The PMA/ionomycin and HBcAg -stimulated up-regulation of IL-17 production
by CD4
+ T cells could be reversed by a neutralizing antibody against IL-6R.
Conclusion: we showed that enhancement of IL-6R expression on CD4
+ T cells upon HBV infection contributes to
increased Th17 response in patients with CHB.
Background
H e p a t i t i sBv i r u s( H B V )i n f e c t i o ni sam a j o rp u b l i c
health problem worldwide, especially in China, where
nearly 7.18% of the population is persistently infected
with HBV and most of them develop chronic hepatitis B
[1,2]. Previous studies have revealed that cellular immu-
nity is critical for the outcome of HBV infection [3].
W h i l eH B V - s p e c i f i cC D 4
+ Tc e l l sa n dC D 8
+ T cells
have been demonstrated to be essential for the control
of HBV infection [4-7], antigen non-specific T cells
i n f i l t r a t i n gt h el i v e ra r er e p o r t e dt ob ei n v o l v e di nt h e
live injury [8,9].
Th17 cells are a new lineage of peripheral CD4
+ T
cells which have been identified as a proinflammatory T
cell subset [10,11]. In human, IL-6 in combination with
TGF-b and IL-1b drive naive CD4
+ T cell to differenti-
ate into Th17 cells [10,12-14]. Th17 cells can produce
multiple cytokines including IL-17A (also known as IL-
17), IL-17F, IL-21 and IL-22 [12,15]. IL-17, a major
effector cytokine of Th17 cells, is involved in mobilizing,
recruiting, and activating neutrophils and leads to mas-
sive tissue inflammation [16]. Recent studies suggested
that Th17 cells also play a central role in the immune-
mediated liver injury [17-20]. In particular, Zhang et al
reported that antigen non-specific Th17 response was
increased in patients with chronic hepatitis B (CHB) and
the peripheral Th17 frequency in CHB patients was
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any medium, provided the original work is properly cited.closely associated with the degree of liver damage which
determined by serum alanine amino-transferase (ALT)
levels and liver histological activity index(HAI) scores
[17]. Consistently, Ge et al demonstrated that the fre-
quency of Th17 cells was positively correlated with
serum ALT levels in CHB patients [20]. However, the
regulatory mechanism of Th17 responses in patients
with HBV infection remains unclear.
In this study, we have found that the increased Th17
response in patients with CHB is correlated with the
enhanced IL-6 receptor (IL-6R) expression on CD4
+ T
cells. In addition, our results indicated that up-regula-
tion of IL-6R expression on CD4
+ T cells is important
for increased Th17 responses in patients with CHB.
These findings suggest that IL-6R can be a novel target
for immunotherapy of hepatitis induced by HBV
infection.
Materials and methods
Subjects
Blood samples were collected from patients with
chronic hepatitis B (CHB, n = 40), subjects of asymp-
tomatic HBV carrier (AsC, n = 25), patients with acute
hepatitis B (AHB, n = 11). All of them were diagnosed
according to the described criteria [17,21,22]. All CHB
patients have not received anti-virus treatment (anti-
viral drug such as interferon or nucleotide analogues)
for at least one year. Individuals with concurrent hepa-
titis C virus, hepatitis D virus, or hepatitis G virus, or
human immunodeficiency virus (HIV) infection, indivi-
duals with autoimmune liver diseases, and individuals
who met clinical or biological criteria of bacterial or
fungal infection were excluded. Twenty-nine age- and
sex-matched healthy donors (HD) were enrolled as
controls. The study protocol was approved by the
ethics committee of Shenzhen Third People’s Hospital
and written informed consent was obtained from each
subject. The basic characteristics of these subjects are
listed in Table 1.
Intracellular staining and flow cytometry analysis
Fluorescence-conjugated antibodies against CD3, CD4,
CD8, IFN-g, IL-17, CD126 (IL-6R) were purchased from
BD Biosciences (San Jose, CA). For intracellular staining,
fresh heparinized peripheral blood (250 μL) was incu-
bated with phorbol 12-myristate 13-acetate (PMA, 50 ng/
ml; Sigma-Aldrich, St. Louis, MO), ionomycin (1 μg/ml;
Sigma-Aldrich), and BFA (0.4 μM, BD PharMingen) in
750 μL RPMI 1640 medium supplemented with 10% fetal
calf serum (FCS) for 6 hours, 37°C. Cells were stained for
cell surface markers first, and then the blood was lysed
with fluorescence-activated cell sorting (FACS) lysing
solution (BD PharMingen) and further permeabilized,
stained with the corresponding intracellular antibody.
Flow cytometry analysis was performed on cells acquired
using a FACSCalibur (BD Biosciences, San Jose, CA) and
data were analyzed using FACSDiva (BD Biosciences)or
FlowJo software (Tristar, San Carlos, CA).
Cell purification
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from fresh whole blood by density gradient centri-
fugation using Lymphoprep (Axis-Shield, Oslo, Norway).
Total CD4
+ T cell were purified by positive selection
using microbeads according to the manufacturer’s
instructions (BD Biosciences). The purity of the CD4
+ T
cell was > 90%. Freshly purified cells were incubated in
complete RPMI 1640 medium containing 10% FCS, 2
mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml
streptomycin.
PBMCs culture
To analyze the effect of HBcAg on IL-6R and IL-17
expression by CD4
+ T cells, PBMCs were cultured in
the absence or presence of HBcAg (10 μg/mL; ARP, Bel-
mont, MA), or LPS(1 μg/ml; Peprotech, Rocky Hill, NJ).
At different time points after incubation as indicated in
legends, cells were harvested and CD4
+ T cells were iso-
lated for quantification of IL-17/IL-6R messenger RNA
Table 1 Clinical Characteristics of the Populations Enrolled in the Study
Group HD
a AsC
b CHB
c AHB
d
Case 29 25 40 11
Sex(male/female) 20/9 16/9 28/12 7/4
Age(years) 24.5 ± 7.5 29.3 ± 9.2 30.6 ± 7.7 25.5 ± 4.0
ALT
e (U/L) < 40 21.9 ± 8.4 264.2 ± 171.2 1169.8 ± 617.8
TBIL
f (μmol/L) < 20 13.7 ± 4.2 27.3 ± 19.3 214.7 ± 116.6
HBV DNA
(log10 copies/mL)
ND
g 3.8 ± 3.6 6.0 ± 1.4 5.1 ± 1.4
HBsAg (+/-) 0/29 25/0 40/0 11/0
HBeAg (+/-) 0/29 13/12 21/19 6/5
HBeAb (+/-) 0/29 12/13 19/21 5/6
Data are expressed as mean ± 1 standard deviation (SD).
a HD, healthy donor;
b AsC, asymptomatic HBV carrier;
c CHB, chronic hepatitis B;
d AHB, acute hepatitis
B;
e ALT, alanine amino-transferase;
f TBil, total bilirubin;
g ND, not determined.
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subjected flow cytometry analysis of IL-6R expression
on CD4
+ T cells. Supernatant were collected for cyto-
kines measurement.
IL-6R blockade treatment
Purified CD4
+ T cells from CHB were incubated in
medium alone or stimulated with PMA (50 ng/ml;
Sigma-Aldrich) and ionomycin (1 μg/ml; Sigma-
Aldrich) for 6 h in the presence of 5 μg/ml of brefeldin
A(0.4 μM, BD PharMingen) or with HBcAg (10 μg/mL,
ARP) for 24 h, neutralizing antibody against IL-6R
(R&D systems, Minneapolis ,M N )w e r ea d d e da tac o n -
centration of 20 μg/ml 30 min before the addition of
PMA or HBcAg. Cells were harvested for intracellular
cytokine staining and analyzed by flow cytometry. Cell
culture supernatants were harvested and the concen-
tration of IL-17, IFN-g was determined by ELISA.
RNA extraction and real-time RT-PCR
Total RNA was extracted from purified CD4
+ T cells
with RNeasy Mini Kit (Qiagen, Santa Clarita, CA)
according to the manufacturer’s protocol. The RNA was
reverse-transcribed to complementary DNA (cDNA)
using oligo (dT) primers at 37°C for 15 minutes and at
85°C for 5 seconds. Quantitative real-time PCR was per-
formed using Applied Biosystems 7500 sequence detec-
tion system. The primers and probes of IL-17(cat:
Hs00936345) and inner control GAPDH(cat:
Hs02758991) for real-time PCR were purchased from
Applied Biosystems (Foster City, CA). IL-6R primer and
probe(Takara, China) sequences were as follows:
forward primer: 5-AAGACAATG CCACTGTT-
CACTG-3;
reverse primer: 5-GGTAGCATGAATAGTTTCCA-
GAGTC-3;
probe: 5-FAM-ACCGACCTCAGCAGCAGCCTCC
TT-Eclipse-3.
Results are expressed in terms of relative mRNA
quantification calculated by using the arithmetic formula
2
-ΔCtΔCt [23].
ELISA assay
The concentrations of IL-17, TGF-b, IL-6, and IL-1b in
culture supernatants and TGF-b,I L - 6 ,I L - 1 b in plasma
were determined by ELISA (R&D Systems, Minneapolis,
MN) following manufacturer’s guidelines.
Statistical Analysis
All statistical tests were performed with SPSS 13.0(Chi-
cago, IL) or Prism 3.0 (GraphPad, La Jolla, CA). The
one-way analysis of variance/Newman-Keuls multiple
comparison test was used for statistical analysis to com-
pare the differences among multiple groups. The
unpaired t test was used to analyze the difference
between two groups. The Wilcoxon matched pair t test
was used to analyze the effect of antigens on IL-6R and
IL-17 expression by CD4
+ T cells in vitro.C o r r e l a t i o n
analysis was performed by Pearson’s t test. For all test,
two-sided P < 0.05 was considered statistically
significant.
Results
Increased Th17 responses were associated with liver
injury in patients with HBV infection
Previous studies within CHB patients suggested that
Th17 cells play an important role in HBV-induced
inflammatory responses [17-20]. To better understand
the role of Th17 cells in HBV infection, we extended
these findings by comparing Th17 responses in patients
with acute hepatitis B (AHB), asymptomatic HBV carrier
(AsC), as well as patients with CHB. Consistent with
previous reports, we found that Th17 responses were
significantly increased in patients with CHB in compari-
son to healthy donors. Moreover, among HBV infected
individuals, Th17 responses were significantly higher in
AHB patients than CHB patients, and both populations
have significantly higher Th17 responses than subjects
with AsC (P < 0.001, Figure 1A and 1B). In contrast,
there was no difference in Th17 responses between AsC
and HD. Furthermore, there were no differences in Th1
responses (the frequency of IFN-g producing CD4
+ T
cells) among different populations (P = ns, Figure 1C).
Therefore, our data confirmed that Th17 responses cor-
related with liver injury in HBV infected individuals.
Cytokines related to Th17 differentiation were increased
in HBV infected subjects
Previous studies suggested that TGF-b or IL-1b facili-
tates Th17 cells development from naïve CD4T cells in
the presence of IL-6 [10,12-14]. To investigate whether
increased Th17 responses observed in patients with
CHB and AHB were due to an altered cytokine envir-
onment induced upon HBV infection, we examined
plasma concentrations of TGF-b,I L - 1 b,a n dI L - 6i n
different populations. Consistent with previous reports
[17,18], we found that concentrations of plasma IL-6,
IL-1b,a n dT G F - b were significantly higher in patients
with CHB and AHB than those in HD (P < 0.001, Fig-
ure 2A, B, C). However, the concentrations of plasma
IL-6 and IL-1b in ASC were not diffe r e n tf r o mt h o s e
of HBV infected individuals with hepatitis (CHB
&AHB). In contrast, the concentration of plasma TGF-
b was significantly different among all four groups. In
addition, correlation analysis showed that the concen-
tration of plasma TGF-b,b u tn o tI L - 6 ,I L - 1 b,s i g n i f i -
cantly correlated with the frequency of Th17 cells in
periphery blood within HBV infected subjects (r =
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b,I L - 6a n dI L - 1 b, all did not correlated with the fre-
quency of periphery Th17 cells (data not shown).
Thus, further experiments are warranted to clarify the
exact role of increased TGF-b,I L - 6a n dI L - 1 b in regu-
lating Th17 development upon HBV infection.
Elevated IL-6R expression on CD4
+ T cells correlated with
an increased Th17 response in HBV infected individuals
Although previous studies showed that IL-6 is critical
for the differentiation of Th17 cells from naïve T cells
[14], the plasma concentration of IL-6 in HBV infected
individuals was not correlated with the level of Th17
responses. Because IL-6 receptor (IL-6R) is mandatory
for the bioactivity of IL-6 and we previously reported
that down-regulation of IL-6R expression on CD4
+ T
cells by Mycobacterium tuberculosis is an important
mechanism underlying reduced Th17 responses in
patients with tuberculosis [24-26], we decided to inves-
tigate whether IL-6R expression is also correlated with
Th17 responses in CHB patients. Our result showed
that the percentage of IL-6R expressing CD4
+ T cells
in peripheral blood of AsC was not different from that
of HD. In contrast, both AHB and CHB patients had
significantly higher percentage of IL-6R expressing
CD4
+ T cells than AsC patients. The percentage of IL-
6R expressing CD4
+ T cells in AHB patients was also
significantly higher than that of CHB patients (Figure
3A, B). Correlation analysis demonstrated that the per-
centage of IL-6R expressing CD4
+ T cells was signifi-
cantly correlated with the frequency of Th17 cells
within all HBV infected subjects (r = 0.836, P < 0.001,
Figure 3C), or within patients with AHB (r = 0.927, P
< 0.001), or CHB(r = 0.683, P < 0.001), or AsC(r =
0.527, P = 0.007). Furthermore, the percentage of IL-
6R expressing CD4
+ T cells was also significantly cor-
related with serum ALT levels in CHB patients (r =
0.400, P = 0.012, Figure 3D). These findings suggested
that alteration of IL-6R expression on CD4
+ Tc e l l s
upon HBV infection might account for increased Th17
response as well as elevated ALT level in patients with
hepatitis B.
Figure 1 Th17 cells were increased in peripheral blood of CHB and AHB patients. (A) Dot plots show intracellular staining for IL-17-
producing CD4 T cells (Th17) and IFN-g-producing CD4 T cells (Th1) in the peripheral blood of HD, AsC, CHB and AHB. Pooled data indicates the
percentage of (B) Th17 and (C) Th1 within CD4 T cells in peripheral blood of HD (n = 29), AsC (n = 25), CHB (n = 40) and AHB (n = 11) patients.
*p < 0.05; ***p < 0.001; Horizontal bars represent the median values; ns, not significance.
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Page 4 of 10Figure 2 The plasma concentrations of IL-6, IL-1b, TGF-b were increased in HBV infected patients. The concentrations of (A) IL-6, (B) IL-1b,
(C)TGF-b in plasma of HD (n = 18), AsC (n = 24), CHB (n = 28), AHB (n = 11). (D) Correlation analysis between the plasma concentration of TGF-
b and the frequency of Th17 in peripheral blood of HBV infected individuals (n = 63). *p < 0.05; **p < 0.01; ***p < 0.005. Horizontal bars
represent the median values of indicated index; Solid line, linear growth trend; r, correlation coefficient. P-values are shown.
Figure 3 Increased expression of IL-6R on CD4 T cells in CHB and AHB patients. (A) Flow cytometric analysis of membrane IL-6R
expression on CD4 T cells of HD, AsC, CHB and AHB. Representative histograms of IL-6R expression on CD4 T cells of each population were
shown. (B) Pooled data indicate the proportion of IL-6R expression on CD4 T cells in HD (n = 29), AsC (n = 25), CHB (n = 40), AHB (n = 11). (C)
Correlation analysis between the frequency of Th17 cells and the proportion of IL-6R expressing on CD4 T cells in HBV infected patients (n = 76),
inserted table indicated the correlation coefficient of two parameters within AHB, CHB and AsC. (D) Correlation analysis between ALT and the
proportion of IL-6R expressing on CD4 T cells in CHB patients. *, p < 0.05; **, p < 0.01; ***, p < 0.001; horizontal bars represented the median
values; solid line, linear growth trend; r, correlation coefficient. P-values are shown.
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by CD4
+ T cells from patients with chronic hepatitis B in
vitro
The finding that increased Th17 responses were corre-
lated with enhanced IL-6R expression on CD4
+ T cells
in CHB patients prompted us to hypothesize that HBV
and/or its products could modulate Th17 responses
through regulating IL-6R expression on CD4
+ T cells.
To test this hypothesis, we investigated the effect of
HBV core antigen on modulating IL-6R expression and
IL-17 production by CD4
+ T cells in vitro. As expected,
incubation of PBMCs from CHB patients in the pre-
sence of HBcAg not only resulted in significantly
enhanced IL-6R expression by CD4
+ T cells at both
mRNA (Figure 4A) and protein level (Figure 4C), but
also increased IL-17 mRNA level by CD4
+ T cells (Fig-
ure 4B) and elevated IL-17 production in supernatant of
PBMCs culture (Figure 4D). In comparison, no
significant enhancement effect on IL-6R and IL-17
expression was observed when PBMCs were incubated
with LPS. Kinetics analysis showed the effect of HBcAg
on enhancing IL-17 and IL-6R mRNA expression could
be observed as early as 4 hours and peaked at 12 hours
after treatment (Figure 4A and 4B).
To determine whether in vivo chronic exposure to
HBV infection influences the capability of CD4
+ T cells
to express IL-6R and IL-17 in response to HBcAg sti-
mulation in vitro, we stimulated CD4
+ T cells from
CHB patients with HBcAg and compared their respon-
siveness with those from HD individuals. We found
that, upon HBcAg stimulation, IL-6R expression on
CD4
+ T cells from CHB patients was significantly
increased. In contrast, IL-6R expression on CD4
+ T cells
from HD was decreased upon HBcAg stimulation (Fig-
ure 4E). Consistently, we found that PBMCs from CHB
patients up-regulated IL-17 production upon HBcAg
Figure 4 HBcAg up-regulate IL-17 and IL-6R expression by CD4 T cells in vitro. PBMCs from CHB patients (n = 8) were cultured in medium
alone, or in the presence of HBcAg (10 μg/ml) or LPS (1 μg/ml). Relative IL-6R (A) and IL-17(B) mRNA expression of CD4 T cells purified from
cultured cells harvested at indicated time after incubation were determined by real-time RT-PCR; (C) the percentage of IL-6R expression on CD4
T cells in cultured cells collected at indicated time after incubation were determined by flow cytometry; (D) IL-17 production in culture
supernatants harvested at 48 hours after incubation was measured by ELISA. (E) Modulation of IL-6R expression on CD4 T cells after incubation
with HBcAg for 24 hours and (F) IL-17 production after incubation with HBcAg for 48 hours in CHB patients (n = 8) and HD (n = 8). The
percentage of increase of IL-6R on CD4 T cells was calculated by dividing the frequencies of IL-6R expressing CD4 cells determined by flow
cytometry cultured in medium alone with those cultured in the presence of HBcAg. Similar formulation was used to calculate the percentage of
increase of IL-17 production measured by ELISA in culture supernatant. *, P < 0.05; **, p < 0.01, ***, P < 0.001; the bars represent means with
standard deviations. Horizontal bars represent the median values.
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(P < 0.001, Figure 4F).
Taken together, these data suggested that modulation
of IL-6R expression on CD4
+ T cells is an important
mechanism underlies the enhanced Th17 responses in
patients with chronic hepatitis B.
An anti-IL-6R antibody inhibited PMA/ionomycin and
HBcAg induced IL-17 production by CD4
+ T cells
To validate whether enhanced IL-6R expression on CD4
+
T cells is causative of elevated Th17 response in patients
with chronic hepatitis B, we studied the effect of blockade
of IL-6R signaling on PMA/ionomycin and HBcAg
induced IL-17 production by purified CD4T cells in vitro.
Blockade of IL-6R signaling by a neutralizing antibody
against IL-6R significantly inhibited PMA/ionomycin-sti-
mulated IL-17 expression by CD4
+ T cells, as demon-
strated by reduced frequency of IL-17 producing CD4
+ T
cells (Figure 5A) and decreased IL-17 secreted in super-
natant of purified CD4
+ T cell culture (Figure 5B). Simi-
larly, treatment with anti-IL-6R significantly inhibited
HBcAg-induced IL-17 production by CD4
+ Tc e l l s .
Moreover, no effect of IL-6R blocking with anti-IL-6R on
IFN-g production by CD4
+ T cells has been observed
(Figure 5A and 5B). Thus, these data confirmed that
enhancement of IL-6R expression on CD4
+ T cells
accounted, at least partially, for the elevated Th17
responses in patients with chronic hepatitis B.
Figure 5 Blockade of IL-6R signaling inhibited PMA/ionomycin and HBcAg induced IL-17 production by CD4 T cell. Purified CD4 T cells
from CHB patients (n = 4) were cultured in medium alone (blank), in the presence of PMA (50 ng/ml) and ionomycin (1 μg/ml) for 6 h (P+I), or
in the presence of HBcAg (10 μg/mL) for 24 h, without or with neutralizing antibody against IL-6R (anti-IL-6R, 20 μg/ml). Cells and supernatant
were harvested at 6 hours for P+I stimulation, and 24 hours for HBcAg stimulation, with or without anti-IL-6R. (A) The frequency of IFN-g- and IL-
17- producing CD4 T cells were determined by flow cytometry analysis. Representative dot plots showed IFN-g- and IL-17- expressing cells within
gated CD3CD4 T cells. (B) IFN-g and IL-17 production released in supernatant of CD4 T cells culture was measured by ELISA. *, P < 0.05; **, p <
0.01, ns, not significant.
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cytokines production by PBMCs in vitro
The finding that elevated plasma TGF-b, IL-1b, and IL-6
in HBV infected individuals suggested that HBV may
have direct effect in inducing these cytokines produc-
tion. To test this hypothesis, we investigate the effect of
HBcAg on modulating cytokine production by PBMCs.
We found both PBMCs (Figure 6) secreted significantly
more TGF-b,I L - 6a n dI L - 1 b upon HBcAg stimulation
than cultured with medium alone. Notably, similar
effects were also observed in PBMCs culture in the pre-
sence of LPS. Since variety of pathogens contains LPS,
our data suggested that both HBV and/or bacterial
pathogens superinfected post onset of HBV infection
could induce cytokines milieu that facilitates the differ-
entiation of Th17 response.
Discussion
Recent studies have shown that Th17 responses were
significantly increased in patients with CHB. Correlation
analysis also suggested that Th17 cells play an important
role in inflammatory response and cell mediated liver
i n j u r yo fC H Bp a t i e n t s[ 1 7 - 2 0 ] .I nt h i ss t u d y ,w e
extended these observations by finding that Th17
responses were even significantly higher in AHB patients
than CHB patients. In contrast, Th17 responses were
not different between asymptomatic HBV carriers and
healthy donors. Taken together, these data provided
substantial evidences that Th17 cells contribute to
inflammatory responses and cell-mediated liver injuries
in individuals with HBV infection. Accordingly, under-
standing the regulatory mechanism of Th17 responses
in HBV infected individuals is of particular importance,
considering it may provide novel strategies for the treat-
ment of patients with hepatitis B.
In attempt to investigate the mechanism underlying
the increased Th17 response in patients with CHB, we
first looked at the cytokine milieu related to the Th17
differentiation and found that TGF-b,I L - 6a n dI L - 1 b
were increased in plasma of HBV infected individuals,
irrespective their clinical manifestation. Consistent with
these findings, in vitro experiments showed that PBMCs
produced TGF-b, IL-1b, and IL-6 upon stimulation with
HBcAg. However, correlation analysis indicated that
only the concentration of plasma TGF-b,b u tn o tI L - 6
nor IL-1b, significantly correlated with increased Th17
responses in HBV infected patients. Thus, unlike the
inhibitory role TGF-b plays during the HCV-specific
Th17 response [27], TGF-b may facilitate the develop-
ment of Th17 responses in HBV infected subjects.
Nevertheless, because TGF-b is also involved in CD4
+
CD25
+ regulatory T cells (Treg) differentiation and our
previous study have found that the concentration of
plasma TGF-b in CHB patients also correlated with the
frequency of Treg [28], the exact role of TGF-b in regu-
lating Th17 response as well as balancing between Th17
and Treg in HBV infected individuals remains to be
elucidated.
Consistent with our previous finding in patients with
tuberculosis, we found IL-6R expression on CD4
+ T
cells, but not plasma IL-6, correlated with the Th17
response in HBV infected individuals [29]. However,
unlike Mycobacterium tuberculosis antigens which
down-regulated IL-6R expression on CD4
+ T cells from
patients with tuberculosis, HBV antigen (HBcAg) up-
regulated IL-6R expression on CD4
+ T cells from
patients with CHB. More importantly, our in vitro data
validated that blockade of IL-6R signaling on CD4
+ T
cells significantly inhibited antigen non-specific (PMA/
Ionomycin-stimulated) and HBcAg antigen-specific IL-
17, but not IFN-g,p r o d u c t i o nb yC D 4
+ T cells, which
was not surprised considering the fact that no require-
ment of IL-6 for Th1 differentiation. Thus, while both
infections modulate IL-6R expression on CD4
+ T cells,
the effect of Mycobacterium tuberculosis infection was
markedly different from that of HBV infection. In addi-
tion, the difference was likely due to in vivo “tuning” of
CD4
+ T cells by chronic exposure to inflammatory
environment superimposed by HBV infection (including
circulating HBV antigens), since HBcAg, similar to
Mycobacterium tuberculosis antigens, down-regulated
IL-6R expression on CD4
+ T cells in healthy donors.
While further investigations are warranted to identify
the exact mechanisms that account for “tuning” CD4
+ T
cells in vivo,c i r c u l a t i n gH B Va n t i g e n sa sw e l la st h e
cytokines induced by HBV infection might be most
potential candidates that are responsible for such differ-
ent effect. For example, elevated TGF-b in patients with
hepatitis B might “tune” CD4
+ Tc e l l sw i t hi n c r e a s e d
Figure 6 HBcAg induced TGF-b,I L - 6a n dI L - 1 b production by
PBMCs in vitro. PBMCs from CHB patients (n = 9) were cultured in
the presence of HBcAg (10 μg/ml) or LPS (1 μg/ml) medium alone.
After 48 h, culture supernatant was collected and the
concentrations of TGF-b, IL-6 and IL-1b were measured by ELISA. *,
P < 0.05. ***, P < 0.001.
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SOCS3 [30,31].
Conclusions
In summary, our present study provided substantial evi-
dences that enhancement of IL-6R expression on CD4
+
T cells by HBV is an important mechanism for
increased Th17 responses in patients with CHB. First,
the percentage of IL-6R expression on CD4
+ T cells cor-
related with the frequency of Th17 cells in peripheral
blood in vivo. Second, HBcAg up-regulated IL-6R and
IL-17 expression by CD4
+ T cells from CHB patients in
vitro. Third, the blockade of IL-6R signaling reversed
the increase of IL-17 production by CD4
+ T cells. Com-
bined with previous reports about the usefulness of neu-
tralizing anti-IL-6R monoclonal antibody to treat
autoimmune diseases via inhibiting Th17 responses
[32-34], our finding suggests a novel strategy for treating
CHB patients, e.g. inhibiting IL-6R expression by anti-
IL-6R antibodies to restrain Th17-mediated liver
damage.
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